Medasense’s NOL® technology for nociception monitoring is now compatible with Philips IntelliVue Patient Monitors. 

Medasense announces positive results from clinical outcome studies, evaluating the role of the NOL^® technology in guiding opioid administration during surgery for improved outcomes.

We are happy to share with you the Medasense received approval to market the PMD-200™ system in Australia.

The PMD-200™ and its NOL^® index are currently commercially available in

We are proud to share with you that the trademark “NOL NOCICEPTION LEVEL INDEX” is approved and registered as Medasense’s trademark in the Europe and in the US!

Medasense won the 2017 Center of Excellence in Wireless and Information Technology (CEWIT) Startup Contest at State University of New York, Stonybrook!
cewit.org/conference2017

We are excited to share that Medasense’s technology was chosen to be highlighted in the British Journal of Anaesthesia (BJA) review article “Digital innovations and emerging technologies for enhanced recovery programmes”.

We are pleased to share with you the exciting news that Medasense has received AMAR approval to sell our pain (Nociception) monitoring system in Israel!
Israeli anesthesiologists are now able to join their European colleagues, who are 

Medasense featured in Innovations in Pharmaceutical Technology publication.
Read our article written by CEO, Galit Zuckerman-Stark, to learn how an objective approach could help healthcare professionals better assess pain.

Medasense featured as one of 106 Artificial Intelligence (AI) Startups In Healthcare by CB Insights website, under the Emergency Room & Surgery section.

Read the article here

Read the publication regarding the PMD-200™ pain monitoring device here (in Italian)